Skip to content
DataLookout
Menu

NCT07118579

Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words Show 5 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Aug 2026 to Jun 30, 2026
    • Enrollment target: estimated 114 to confirmed 111
    • Secondary endpoints: details revised at 2 of 6 entries
    • Site details revised
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary and study completion dates: Dec 2025 to Aug 2026
    • Start date changed from estimate of Aug 2025 to Sep 23, 2025
    • Secondary endpoints revised (6)
    • Site details revised
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The incidence of perioperative respiratory adverse events
Timeframe: 5days

Secondary (6)

Anesthesia duration
Emergence time
Extubation time
PACU stay duration
The modified Aldrete score
Show 1 moreShow less
doses of drugs

Arms and interventions

Propofol groupActive comparator

Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)

Remimazolam groupExperimental

Anesthesia induction (0.3-0.5 mg/kg) + Anesthesia maintenance (1-3 mg/kg/h)

Ciprofol groupExperimental

Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)

Drugs: Remimazolam, Propofol, Ciprofol

Sites

1 site in 1 country

  • Tongji HospitalWuhan, Hubei, China